Alto Neuroscience (ANRO) Other Non-Current Assets (2024 - 2026)
Alto Neuroscience (ANRO) posted Other Non-Current Assets of $500000.0 for Q1 2026, up 47.93% sequentially from $338000.0 in Q4 2025, and down 12.13% YoY from $569000.0 in Q1 2025.
Alto Neuroscience (ANRO) Other Non-Current Assets (2024 - 2026) Analysis & Trends
Alto Neuroscience has reported Other Non-Current Assets for 3 years, with the latest figure at $500000.0 in Q1 2026.
- Quarterly Other Non-Current Assets fell 12.13% year-over-year to $500000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $500000.0 (down 12.13% YoY) and the FY2025 annual result came in at $338000.0, up 8350.0% from the prior year.
- Other Non-Current Assets climbed to $500000.0 in Q1 2026 per ANRO's latest filing, from $338000.0 in the prior quarter.
- Over five years, Other Non-Current Assets peaked at $570000.0 in Q3 2025 and troughed at $4000.0 in Q2 2024.
- A 3-year average of $338111.1 and a median of $500000.0 in 2024 frame the typical range for Other Non-Current Assets.
- The sharpest annual moves came in 2025 and 2026: Other Non-Current Assets jumped 12400.0% in 2025, then dropped 12.13% in 2026.
- Over 3 years, Other Non-Current Assets stood at $4000.0 in 2024, then surged by 8350.0% to $338000.0 in 2025, then soared by 47.93% to $500000.0 in 2026.
- According to Business Quant data, Other Non-Current Assets over the past three periods registered $500000.0, $338000.0, and $570000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 2.31 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 124.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 42.45 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 109.58 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 18,237.65 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 62.96 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 65.13 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 104.44 Mn |
| 10 | Alto Neuroscience | 1.13 Bn | 1.13 Bn | - | 500,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 500,000.00 |
| Mar 31, 2026 | 500,000.00 |
| Dec 31, 2025 | 338,000.00 |
| Sep 30, 2025 | 570,000.00 |
| Jun 30, 2025 | 500,000.00 |
| Mar 31, 2025 | 569,000.00 |
| Dec 31, 2024 | 4,000.00 |
| Sep 30, 2024 | 500,000.00 |
| Jun 30, 2024 | 4,000.00 |
| Mar 31, 2024 | 58,000.00 |